BusinessOtonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDABy Nasdaq OMXApr 18, 2016, 11:30 AM UTC
BusinessOtonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s DiseaseBy Nasdaq OMXMar 23, 2016, 11:30 AM UTC
BusinessOtonomy Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 7, 2016, 9:14 PM UTC
BusinessOtonomy Initiates Phase 2 Clinical Trial of OTIPRIO™ in Pediatric Patients With Acute Otitis Media With Tympanostomy TubesBy Nasdaq OMXMar 3, 2016, 12:30 PM UTC
BusinessOtonomy to Present at Cowen and Company Health Care ConferenceBy Nasdaq OMXFeb 29, 2016, 12:30 PM UTC
BusinessOtonomy to Report Fourth Quarter and Full Year 2015 Financial Results and Provide Corporate UpdateBy Nasdaq OMXFeb 26, 2016, 12:30 PM UTC
BusinessOtonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing LossBy Nasdaq OMXJan 26, 2016, 12:05 PM UTC
